100 related articles for article (PubMed ID: 642513)
1. Response of intramuscular Walker 256 rat tumor to sustained-release cyclophosphamide and ARA-C capsules.
Fu JC; Moyer DL; Cuevas J; Cummings L; Eaton A; Elshire D
J Surg Oncol; 1978; 10(2):133-40. PubMed ID: 642513
[TBL] [Abstract][Full Text] [Related]
2. Effects of subcutaneously implanted sustained-release cyclophosphamide capsules on Walker 256 solid rat tumor.
Fu JC; Moyer DL; Cuevas J; Young R; Elshire D
J Surg Oncol; 1977; 9(3):235-41. PubMed ID: 875393
[TBL] [Abstract][Full Text] [Related]
3. Response of lymphoid leukemia L1210 in mice to implantable sustained release cytosine arabinoside capsules.
Fu JC; Khwaja T; Moyer DL; Cummings L; Varvan J; Elshire D
J Surg Oncol; 1978; 10(1):1-7. PubMed ID: 628213
[TBL] [Abstract][Full Text] [Related]
4. Effect of cyclophosphamide and mitomycin C on Walker carcinosarcoma 256 grown in liver and muscle.
Mathur IS; Singh NB; Gupta HP; Gupta SK
Indian J Med Res; 1979 Feb; 69():284-9. PubMed ID: 429035
[No Abstract] [Full Text] [Related]
5. Chemotherapy of experimental meningeal carcinomatosis.
Ushio Y; Posner JB; Shapiro WR
Cancer Res; 1977 Apr; 37(4):1232-7. PubMed ID: 844048
[No Abstract] [Full Text] [Related]
6. Antitumor activity of prolonged-release derivative of cytosine arabinoside, cytosine arabinoside-agarose conjugate.
Hashida M; Kojima T; Muranishi S; Sezaki H
Gan; 1978 Dec; 69(6):839-43. PubMed ID: 750275
[TBL] [Abstract][Full Text] [Related]
7. Different sensitivity of two Walker 256 carcinoma lines to cyclophosphamide: correlation with drug distribution, biotransformation and macromolecule binding.
Donelli MG; Guaitani A; Torti L; Damia G; Corti F; Bianchi M; Tortoreto M; Pantarotto C; Bartosek I
Oncology; 1986; 43(4):257-63. PubMed ID: 3725287
[TBL] [Abstract][Full Text] [Related]
8. Aprotinin and growth of Walker 256 carcinosarcoma in the rat.
Thomson AW; Pugh-Humphreys RG; Horne CH; Tweedle DJ
Br J Cancer; 1977 Apr; 35(4):454-60. PubMed ID: 300627
[TBL] [Abstract][Full Text] [Related]
9. Study of antitumor activity of antibodies to TNF-α on Walker carcinosarcoma model.
Yurlova EI; Krylova SG; Dugina JL; Epstein OI
Bull Exp Biol Med; 2013 Sep; 155(5):673-5. PubMed ID: 24288736
[TBL] [Abstract][Full Text] [Related]
10. Sustained delivery of cytarabine-loaded vesicular phospholipid gels for treatment of xenografted glioma.
Qi N; Cai C; Zhang W; Niu Y; Yang J; Wang L; Tian B; Liu X; Lin X; Zhang Y; Zhang Y; He H; Chen K; Tang X
Int J Pharm; 2014 Sep; 472(1-2):48-55. PubMed ID: 24914829
[TBL] [Abstract][Full Text] [Related]
11. [Antitumor activity of CPT-11 against rat Walker 256 carcinoma].
Furuta T; Yokokura T; Mutai M
Gan To Kagaku Ryoho; 1988 Sep; 15(9):2757-60. PubMed ID: 3415271
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous infusion of high-dose cytosine arabinoside with cyclophosphamide followed by total body irradiation and marrow infusion for the treatment of patients with advanced hematological malignancy.
Petersen FB; Appelbaum FR; Buckner CD; Sanders JE; Clift RA; McGuffin R; Bearman SI; Flournoy N; Thomas ED
Bone Marrow Transplant; 1988 Nov; 3(6):619-24. PubMed ID: 3063329
[TBL] [Abstract][Full Text] [Related]
13. [Kinetics of regression and relapse of Walker carcinosarcoma treated with alkylating agents].
Parkanskiĭ MN; Konovalova NP; Emanuél' N
Izv Akad Nauk SSSR Biol; 1973; (1):144-6. PubMed ID: 4218850
[No Abstract] [Full Text] [Related]
14. Combination chemotherapy for children with acute lymphocytic leukemia who fail to respond to standard remission-induction therapy.
Lay HN; Ekert H; Colebatch JH
Cancer; 1975 Oct; 36(4):1220-2. PubMed ID: 1058044
[TBL] [Abstract][Full Text] [Related]
15. Development of a cell kinetic approach to curative therapy of acute myelocytic leukemia in remission using the cell cycle-specific drug 1-beta-D-arabinofuranosylcytosine in a rat model.
Vaughan WP; Burke PJ
Cancer Res; 1983 May; 43(5):2005-9. PubMed ID: 6572561
[TBL] [Abstract][Full Text] [Related]
16. Cyclophosphamide, cytosine arabinoside and methotrexate versus cytosine arabinoside and thioguanine for acute non-lymphocytic leukemia in adults.
Skeel RT; Costello W; Bennett JM; Oken MM; Tobin MS; Bertino JR; Marsh JC; Carbone PP
Cancer; 1980 Jan; 45(2):224-31. PubMed ID: 6985830
[TBL] [Abstract][Full Text] [Related]
17. Improvement of therapeutic effects of cytosine-arabinoside on Walker-carcinosarcoma after different synchronization with hydroxyurea.
Mattern J; Wayss K; Volm M
Eur J Cancer (1965); 1978 May; 14(5):603-5. PubMed ID: 348480
[No Abstract] [Full Text] [Related]
18. Cytarabine induced cerebellar neuronal damage in juvenile rat: correlating neurobehavioral performance with cellular and genetic alterations.
Patel RS; Rachamalla M; Chary NR; Shera FY; Tikoo K; Jena G
Toxicology; 2012 Mar; 293(1-3):41-52. PubMed ID: 22212197
[TBL] [Abstract][Full Text] [Related]
19. Slow releasing of ara-C from poly(2-hydroxyethyl methacrylate) and poly(2-hydroxyethyl methacrylate-co-N-vinyl-2-pyrrolidone) hydrogels implanted subcutaneously in the back of rats.
Blanco MD; Trigo RM; Teijón C; Gómez C; Teijón JM
Biomaterials; 1998; 19(7-9):861-9. PubMed ID: 9663763
[TBL] [Abstract][Full Text] [Related]
20. Combined therapeutic trial in multiple sclerosis: hydrocortisone hemisuccinate with cyclophosphamide or cytosine arabinoside.
Cendrowski W
Acta Neurol Belg; 1973; 73(4):209-19. PubMed ID: 4770124
[No Abstract] [Full Text] [Related]
[Next] [New Search]
